State Food and Drug Administration, Ministry of Public Security, National Health Commission
Announcement on the adjustment of the list of narcotic drugs and psychotropic substances
(54 of 2024)
In accordance with the relevant provisions of the Regulations on the Administration of Narcotic Drugs and Psychotropic Substances, the State Drug Administration, the Ministry of Public Security, and the National Health Commission have decided to adjust the list of psychotropic substances. The announcement is as follows:
1. Dextromethorphan, diphenoxylate-containing combination preparations, nalfuraphine and lorcaserin are included in the list of Class II psychotropic drugs.
2. The midazolam API and injection will be adjusted from Class II psychotropic drugs to Class I psychotropic drugs, and other unilateral preparations of midazolam will remain Class II psychotropic drugs.
This announcement will come into force on July 1, 2024.
The announcement is hereby made.
State Food and Drug Administration, Ministry of Public Security
National Health Commission
April 30, 2024
No.01
About dextromethorphan
Dextromethorphan, commonly referred to as dextromethorphan hydrobromide, is a derivative of dextromorphine with antitussive effects and is often used to treat cough caused by various respiratory infections.
Abuse Hazards
Dextromethorphan is addictive when taken in large amounts, and there will be euphoria, drunkenness, high excitement, paresthesia, visual and auditory hallucinations, etc.; If the dosage is continued to be increased, central depression such as decreased responsiveness and orientation, drowsiness, coma, respiratory depression and even death may occur.
No.02
About midazolam
Midazolam injection, which is used for pre-anesthetic administration, general anesthesia induction and maintenance; Midazolam maleate tablets for short-term treatment of various insomnia; Midazolam buccal mucosal solution for the treatment of acute seizures in children.
Abuse Hazards
Misuse of midazolam may cause drowsiness, ataxia, slurred speech, memory loss, slow or difficult breathing, anxiety, insomnia, headaches, etc. Abrupt discontinuation of treatment may produce withdrawal symptoms or rebound phenomena, including excessive sweating, palpitations, dry mouth, dizziness, stomach upset, hand tremors, insomnia, nausea or vomiting, hallucinations, anxiety, psychomotor agitation, grand mal seizures, and in severe cases, disrepresentation, hyperacusis, numbness and tingling in the hands and feet, sensitivity to light, noise and physical contact, hallucinations or convulsions.
When taking medicines
Strict medical advice should be followed
Use the drug according to the drug instructions
Avoid overdose and over-range use
Overdose not only does not cure the disease, but also injures the body
Long-term use is more likely to develop addiction
Call on the broad masses of the people to use drugs safely
Say "No" to Substance Abuse Together
Source: Official website of the State Drug Administration, CCTV.com, China drug control